I. THE INFRASTRUCTURE OF CAPTURE: Vertical Integration & Market Power
The supply chain for prescription drugs is dominated by a few vertically integrated conglomerates that act as payer, price negotiator, and pharmacy. This structure removes market checks and balances.
The Evidence:
Extreme Concentration: The FTC's 2024 interim report finds the top three Pharmacy Benefit Managers (PBMs)—CVS Caremark, Express Scripts, and OptumRx—processed nearly 80% of the approximately 6.6 billion prescriptions dispensed in 2023. The top six PBMs managed over 90%[reference:0].
Self-Preferencing & Steering: The same report details that vertically integrated PBMs have the incentive and ability to steer patients to their own affiliated pharmacies and away from independent competitors, a conflict of interest that disadvantages unaffiliated businesses[reference:1].
Direct Patient Impact: The FTC report notes that this concentrated power contributes to affordability crises, with nearly 30% of surveyed Americans reporting they have rationed or skipped doses of their prescribed medicines due to high costs[reference:2].
Systemic Implication:
When the entity that approves the drug, the entity that pays for it, and the entity that dispenses it are parts of the same financial organism, a coverage denial is not a clinical judgment but an internal risk transfer.
II. THE DETERRENCE PROTOCOL: Prior Authorization & Automated Denials
Prior authorization (PA) is justified as a cost-control and safety measure. Operationally, it functions as a high-volume denial gateway that relies on patient and provider fatigue.
The Evidence:
* Clinical Harm: A 2024 AMA survey of physicians found that 29% reported PA requirements had led to a serious adverse event (including hospitalization, permanent impairment, or death) for a patient under their care[reference:3].
* Treatment Abandonment: The same survey found 82% of physicians report that PA processes can lead to patients abandoning their prescribed treatment[reference:4].
* The "False Negative" Rate: A KFF analysis of 2022 Medicare Advantage data reveals the scale and inaccuracy of this gateway. Plans processed 46.2 million PA requests, denying 7.4% of them[reference:5]. However, when those denials are appealed, 83.2% are overturned[reference:6].
* The Appeal Gap: The system relies on patient non-appeal. In 2022, only 9.9% of all PA denials were formally appealed[reference:7].
* Automation & AI: Physicians express concern that augmented intelligence (AI) tools are being used by insurers to create "systematic batch denials with little or no human review"[reference:8].
Systemic Implication:
A process with an 83% error rate upon review cannot be considered a reliable clinical filter. It is a barrier that statistically succeeds because over 90% of patients do not challenge the initial denial.
III. THE ECONOMIC FILTER: Cost-Sharing & Prescription Abandonment
When administrative hurdles fail to deter care, known cost-sharing thresholds trigger "voluntary" abandonment, directly reducing payer liability.
The Evidence:
Aggregate Abandonment: According to an analysis of IQVIA data, patients starting new therapies abandoned 98 million prescriptions at the pharmacy counter in 2023[reference:9].
Novel Therapy Gap: For new, often life-saving therapies, the abandonment problem is acute. More than half of new prescriptions for novel therapies go unfilled, and only 31% of patients remain on therapy after one year[reference:10].
The Cost-Sharing Cliff: While recent aggregate data on specific dollar thresholds is guarded, the relationship is well-established. A 2018 study cited by PhRMA, using IQVIA data, found that 69% of commercially insured patients abandoned new prescriptions when their cost-sharing exceeded $250[reference:11]. Industry analyses consistently show abandonment rates rise sharply as out-of-pocket costs move from $0 to $50 and beyond.
Systemic Implication: Formulary designers and benefit structures utilize these known price sensitivity curves. Placing a medication on a high co-insurance tier is a financial lever that predictably leads to non-fulfillment, transferring the cost of worsened health outcomes to the broader system.
IV. CONCLUSION: The Structural Algorithm
The defining characteristic of U.S. healthcare administration is not inefficiency but a perverse efficiency in filtering out utilization. The system's architecture creates a sequential attrition algorithm:
1. Consolidation limits consumer choice and creates conflicts of interest[reference:12].
2. Authorization creates a denial-heavy process with a high reversal rate, relying on appeal fatigue[reference:13][reference:14].
3. Cost-Sharing triggers economically predictable abandonment at scale[reference:15].
The outcome is a system where accessing pre-paid care requires patients to perform unpaid "shadow work"—navigating opaque formularies, prior authorization appeals, and financial assistance programs—a burden that falls most heavily on the sick and vulnerable.
SOURCE AUDIT: VERIFIED CITATIONS
* [reference:16][reference:17][reference:18] Federal Trade Commission. (2024, July 9). FTC Releases Interim Staff Report on Prescription Drug Middlemen [reference:19].
* [reference:20][reference:21][reference:22] AJMC. (2025, February 24). AMA Survey Highlights Growing Burden of Prior Authorization on Physicians, Patients [reference:23].
* [reference:24][reference:25][reference:26] KFF. (2024, August 8). Medicare Advantage Plans Denied a Larger Share of Prior Authorization Requests in 2022 Than in Prior Years [reference:27].
* [reference:28] Managed Healthcare Executive. (2024, May 7). IQVIA: Medicine Spending Expected to Grow 4% to 7% [reference:29].
* [reference:30] PhRMA. (2018, August 23). 69 percent of patients abandon medicines when cost sharing is more than $250 [reference:31].